MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$3.72
+0.05 (+1.36%)
Open$3.68
Previous Close$3.67
Day High$3.73
Day Low$3.67
52W High$7.99
52W Low$3.03
Volume—
Avg Volume1.19M
Market Cap546.63M
P/E Ratio17.81
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+549.2% upside
Current
$3.72
$3.72
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 416.45M | 358.82M | 190.63M |
| Net Income | 48.32M | 37.47M | 27.70M |
| Profit Margin | 11.6% | 11.0% | 14.5% |
| EBITDA | 64.96M | 53.17M | 34.17M |
| Free Cash Flow | — | — | 29.04M |
| Rev Growth | +16.1% | +16.1% | +8.9% |
| Debt/Equity | 0.07 | 0.07 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |